{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:04:44Z","timestamp":1760821484724,"version":"3.40.5"},"reference-count":26,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Res Treat"],"abstract":"<jats:p>Introduction: Endometrium cancer is the most common gynecological malignancy in developed countries. In this study, we aimed to investigate the effect of HER2 positivity on prognosis in endometrial cancer. Methods: In our study, patients admitted to our clinic with a diagnosis of endometrial cancer between September 2019 and December 2023 were retrospectively evaluated. Human epidermal growth factor receptor 2 (HER2) immunohistochemistry was performed in 121 patients. HER2-low group (HER2 score: 0 and 1) and HER2-high group (HER2 score: 2 and 3) were defined according to the HER2 immunohistochemistry score in the pathology, and patients were compared accordingly. Results: We observed that 97 (80.2%) of the patients were in the HER2-low group, while 24 (19.8%) were in the HER2-high group. In the OS analysis, age (p = 0.381), menopausal status (p = 0.511), ECOG performance status (p = 0.087), histological type of tumor (p = 0.727), pathological grade (p = 0.206), serum LDH (p = 0.091), and albumin (p = 0.315) levels did not affect the prognosis. Patients with lower FIGO stage (p = 0.003) and HER2-high patients (p = 0.040) had better survival outcomes. Multivariable analysis showed that FIGO stage (p = 0.004) and HER2 status (p = 0.040) were independent risk factors affecting survival in endometrial cancer. Conclusion: As a result of our study, it was observed that FIGO stage and HER2 status were independent risk factors affecting OS in endometrial cancer patients. HER2-high group had a better prognosis than HER2-low group. <\/jats:p>","DOI":"10.1159\/000542900","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T17:01:39Z","timestamp":1732899699000},"page":"75-81","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic Significance of HER2 Positivity in Endometrium Cancer"],"prefix":"10.1159","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4650-248X","authenticated-orcid":false,"given":"Serhat","family":"Sekmek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dogan","family":"Bayram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irfan","family":"Karahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismet","family":"Seven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perihan","family":"Perkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamil Hakan","family":"Muftuoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oznur","family":"Bal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bulent","family":"Yalcin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dogan","family":"Uncu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efnan","family":"Algin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.08.025"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.12.039"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67063-8"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn169"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-47033-8"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03522-9"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2533"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0785"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq421"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0149"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12207"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/10668969221102529"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.14923"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-002230"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.009"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.05.018"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02141-0"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2015.07.008"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2008.11.014"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1245\/aso.2003.05.010"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03655-x"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2012.02240.x"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1080\/13697137.2024.2376189"}],"container-title":["Oncology Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/ort\/article-pdf\/48\/3\/75\/4306612\/000542900.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/ort\/article-pdf\/48\/3\/75\/4306612\/000542900.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:04:01Z","timestamp":1745420641000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000542900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,3]]},"published-print":{"date-parts":[[2025,3,11]]}},"URL":"https:\/\/doi.org\/10.1159\/000542900","archive":["Portico"],"relation":{},"ISSN":["2296-5270","2296-5262"],"issn-type":[{"type":"print","value":"2296-5270"},{"type":"electronic","value":"2296-5262"}],"subject":[],"published":{"date-parts":[[2024,11,29]]}}}